December 23rd 2022
Patients with relapsed/refractory follicular lymphoma — a group that traditionally has limited treatment options — now have a new bispecific antibody available.
August 22nd 2022
The combination treatment demonstrated survival and safety results similar to those of chemotherapy for patients with advanced, untreated follicular lymphoma.
July 8th 2022
The FDA approval of Breyanzi, a novel CAR-T cell therapy, provides many patients with lymphoma a new treatment option that can be used earlier in the course of their disease, according to an expert.
July 7th 2022
The priority review comes following positive clinical trial results, which may lead to a shift in the treatment paradigm for follicular lymphoma, according to an expert.
May 31st 2022
Kymriah, a CAR-T cell therapy, was approved by the Food and Drug Administration for the treatment of patients with pretreated, relapsed/refractory follicular lymphoma.
February 25th 2022
Treatment with TRPH-222 led to lasting responses in certain patients with relapsed/refractory B-cell non-Hodgkin lymphomas, warranting a larger investigation into the drug, according to the researchers.
January 24th 2022
Kymriah may represent a more effective option than currently available treatments for patients with heavily pretreated follicular lymphoma, according to an expert from The University of Texas MD Anderson Cancer Center.
December 23rd 2021
New findings show that 43% of patients with certain blood cancers produced COVID-19 antibodies after receiving a third full dose of the mRNA vaccine.
November 1st 2021
The Food and Drug Administration will review parsaclisib for the treatment of patients with follicular lymphoma, marginal zone lymphoma and mantle cell lymphoma.
October 28th 2021
Kymriah was granted a priority review for the treatment of pretreated patients with relapsed or refractory follicular lymphoma.
October 14th 2021
“We tried very hard, my daughter and I, to have a daughter-father relationship, not a daughter-doctor relationship,” said Dr. Michael Weiner on this episode of the “CURE® Talks Cancer” podcast, in which he discussed his career, his own cancer journey and his daughter’s diagnosis.
March 6th 2021
This accelerated FDA approval is the first CAR T-cell therapy approved for the treatment of patients with indolent follicular lymphoma.
February 17th 2021
Local access to national cancer studies allows patients to receive promising new treatments in the most convenient setting possible: Their own community.
February 5th 2021
The Food and Drug Administration has granted an accelerated approval to Ukoniq for the treatment of certain adults with previously treated relapsed or refractory marginal zone lymphoma and relapsed or refractory follicular lymphoma.
December 30th 2020
A roundup of some of the most read news and updates in follicular lymphoma in 2020 from CURE®.
December 26th 2020
Aileen Holthaus writes about her first day of chemotherapy for follicular lymphoma, and the challenges it presented.
November 4th 2020
One recently approved drug and two experimental treatments offer the promise of a wider range of options for patients with follicular lymphoma, according to Dr. Germame Ajebo.
October 30th 2020
Bob Meyers and his daughter Leslie Watson have always been close. In fact, they live right down the street from one another in their Georgia neighborhood. So, when Watson received the diagnosis of clear cell carcinoma in the summer of 1996, and then follicular lymphoma later that fall, Meyers was there by her side as her devoted caregiver.
October 27th 2020
In addition to showing clinically meaningful, durable responses, Tazverik (tazemetostat) was generally well-tolerated in heavily pretreated patients with relapsed or refractory follicular lymphoma, according to the results of an open-label, single-arm, multicenter phase 2 study.
October 16th 2020
A study evaluating the efficacy of Aliqopa (copanlisib) in combination with Rituxan (rituximab) in patients with indolent non-Hodgkin’s lymphoma who have relapsed after at least one prior line of therapy also involving Rituxan has met its primary endpoint, according to Aliqopa’s manufacturer, Bayer.
October 15th 2020
Follicular lymphoma treatment options are changing, and according to one expert, immunotherapy could become a major part of therapy sequencing.
October 14th 2020
Dr. Kami J. Maddocks discusses the importance of effective treatments for patients with aggressive follicular lymphoma and the treatment challenges they face.
October 7th 2020
“Collectively, our mature data provide the most definitive evidence supporting current guidelines, that HDT/ASCT should not be offered to unselected patient(s) (with follicular lymphoma) in the frontline setting,” the authors wrote.
August 12th 2020
“These results further support our efforts to reimagine medicine in this incurable malignancy and reach this underserved patient population, who are historically burdened with several years of various treatments,” said Dr. John Tsai.
July 13th 2020
“Having new options is important, particularly when patients have already been through chemotherapy and some of the other therapies that are available,” said Dr. John P. Leonard.
June 18th 2020
The Food and Drug Administration approved Tazverik for adults with relapsed or refractory follicular lymphoma whose tumors are positive for an EZH2 mutation and have received treatment with at least two systemic therapies, as well as patients who have no other treatment options.
My Mastectomy Results Were Not What I Expected
Cancer Survivors, Loved Ones Share How They Advocate
Recognizing Psychological Distress After Cancer
HER2-Positive Breast Cancer Needs Aggressive Treatment, Expert Says